{"id":"vonoprazan-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unlike proton pump inhibitors (PPIs) that irreversibly bind to the H+/K+-ATPase, vonoprazan competitively blocks potassium binding to the pump, allowing for faster onset and offset of acid suppression. This mechanism provides more rapid and sustained acid suppression, making it effective for conditions requiring strong gastric acid reduction. It is particularly useful in treating acid-related disorders and has shown efficacy in Helicobacter pylori eradication regimens.","oneSentence":"Vonoprazan is a potassium-competitive acid blocker that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:38.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Helicobacter pylori eradication (as part of combination therapy)"}]},"trialDetails":[{"nctId":"NCT06851559","phase":"PHASE2","title":"A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks","status":"RECRUITING","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2025-10-30","conditions":"Eosinophilic Esophagitis","enrollment":80},{"nctId":"NCT06340724","phase":"PHASE3","title":"Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-02-15","conditions":"Helicobacter Pylori Infection","enrollment":104},{"nctId":"NCT07224035","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-15","conditions":"H Pylori Infection, H Pylori Gastritis, Gastric Cancer","enrollment":500},{"nctId":"NCT07352098","phase":"NA","title":"7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori","status":"NOT_YET_RECRUITING","sponsor":"Yueyue Li","startDate":"2026-02-01","conditions":"Helicobacter","enrollment":290},{"nctId":"NCT07306988","phase":"PHASE4","title":"Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-04-17","conditions":"HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome","enrollment":120},{"nctId":"NCT07267260","phase":"PHASE2","title":"Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-16","conditions":"Cirrhoses, Liver","enrollment":154},{"nctId":"NCT06831344","phase":"PHASE1","title":"A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2025-02-14","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT07278349","phase":"PHASE1","title":"Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-09-21","conditions":"Erosive Gastritis, Erosive Esophagitis(EE), HELICOBACTER PYLORI INFECTIONS","enrollment":28},{"nctId":"NCT06168084","phase":"PHASE4","title":"Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy","status":"COMPLETED","sponsor":"Yongquan Shi","startDate":"2023-06-06","conditions":"Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer","enrollment":688},{"nctId":"NCT03214081","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Maintenance Therapy of Reflux Esophagitis: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-01","conditions":"Reflux Esophagitis","enrollment":1237},{"nctId":"NCT06660342","phase":"","title":"A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring","status":"RECRUITING","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2025-05-15","conditions":"Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease","enrollment":728},{"nctId":"NCT05343364","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2022-05-09","conditions":"Gastroesophageal Reflux","enrollment":24},{"nctId":"NCT06901375","phase":"EARLY_PHASE1","title":"Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-05","conditions":"Helicobacter Pylori Infection","enrollment":136},{"nctId":"NCT06391177","phase":"PHASE1","title":"A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2024-05-07","conditions":"Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease","enrollment":15},{"nctId":"NCT06576882","phase":"PHASE3","title":"7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-30","conditions":"Helicobacter Pylori Infection, Gastritis, Vonoprazan","enrollment":326},{"nctId":"NCT06642987","phase":"PHASE1","title":"Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2023-10-23","conditions":"Gastric Ulcer","enrollment":30},{"nctId":"NCT05227833","phase":"PHASE3","title":"Vonoprazan Efficacy to Prevent Post Variceal Band Ligation Ulcer","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-02-15","conditions":"Portal Hypertension, Variceal Hemorrhage, Ulcer Hemorrhage","enrollment":284},{"nctId":"NCT06162949","phase":"PHASE3","title":"Vonoprazan for Helicobacter Pylori Eradication in Adolescents","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":"Treatment Effectiveness","enrollment":242},{"nctId":"NCT05649709","phase":"PHASE4","title":"Helicobacter Pylori and Vonoprazan Dual Therapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Nanchang University","startDate":"2023-02-13","conditions":"Helicobacter Pylori","enrollment":504},{"nctId":"NCT06526455","phase":"PHASE4","title":"Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection","status":"NOT_YET_RECRUITING","sponsor":"Shicai Ye","startDate":"2024-08-01","conditions":"Ulcers, Gastric","enrollment":196},{"nctId":"NCT05749081","phase":"PHASE4","title":"Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Nanchang University","startDate":"2023-05-13","conditions":"Helicobacter Pylori Infection","enrollment":324},{"nctId":"NCT06250634","phase":"NA","title":"Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-02-10","conditions":"Helicobacter Pylori Infection","enrollment":806},{"nctId":"NCT05366738","phase":"PHASE1","title":"A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2022-05-18","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT04028466","phase":"PHASE4","title":"Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features","status":"TERMINATED","sponsor":"St. Luke's Medical Center, Philippines","startDate":"2019-05-26","conditions":"GERD, Gastro Esophageal Reflux","enrollment":82},{"nctId":"NCT05719831","phase":"PHASE3","title":"Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-01","conditions":"Helicobacter Pylori Eradication Rate","enrollment":516},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"Helicobacter Pylori Eradication","enrollment":232},{"nctId":"NCT04198363","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-04-30","conditions":"Helicobacter Pylori","enrollment":510},{"nctId":"NCT04753437","phase":"PHASE1","title":"A Study of Vonoprazan in Adults With Helicobacter Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-06","conditions":"Helicobacter Pylori","enrollment":44},{"nctId":"NCT06004401","phase":"NA","title":"The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-20","conditions":"The Eradication Rate of Helicobacter Pylori","enrollment":400},{"nctId":"NCT03214198","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-01","conditions":"A History of Gastric or Duodenal Ulcers","enrollment":1304},{"nctId":"NCT04729101","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2021-01-28","conditions":"Healthy Participants","enrollment":44},{"nctId":"NCT04545944","phase":"PHASE1","title":"Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2020-09-15","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT05590286","phase":"PHASE4","title":"A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2022-06-01","conditions":"Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor","enrollment":100},{"nctId":"NCT04124926","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-10-28","conditions":"Erosive Esophagitis","enrollment":1027},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":"Helicobacter Pylori Infection","enrollment":1046},{"nctId":"NCT04558216","phase":"PHASE1","title":"Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants","status":"WITHDRAWN","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2020-09-30","conditions":"Healthy Participants","enrollment":""},{"nctId":"NCT05196945","phase":"PHASE4","title":"Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication of Helicobacter Pylori -- a Multicenter, Randomized, Parallel Controlled Study","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-03-31","conditions":"Helicobacter Pylori Eradication Rate","enrollment":316},{"nctId":"NCT05135793","phase":"PHASE1","title":"Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2021-01-19","conditions":"Healthy","enrollment":29},{"nctId":"NCT04568772","phase":"PHASE1","title":"Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-11-25","conditions":"Gastroesophageal Reflux Disease","enrollment":19},{"nctId":"NCT03050307","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-17","conditions":"Gastric Ulcer","enrollment":234},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533},{"nctId":"NCT03214094","phase":"","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-01","conditions":"Gastric or Duodenal Ulcers","enrollment":1119},{"nctId":"NCT02388737","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-04-01","conditions":"Erosive Esophagitis","enrollment":703},{"nctId":"NCT02743949","phase":"PHASE2","title":"Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-14","conditions":"Gastroesophageal Reflux","enrollment":256},{"nctId":"NCT03214952","phase":"","title":"Drug Use Surveillance of Vonoprazan for \"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-01","conditions":"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis","enrollment":3183},{"nctId":"NCT02388724","phase":"PHASE3","title":"Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03-24","conditions":"Erosive Esophagitis","enrollment":481},{"nctId":"NCT03219723","phase":"","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-09-01","conditions":"Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other","enrollment":560},{"nctId":"NCT02037477","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-01","conditions":"Healthy Volunteers","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vonoprazan Tablets","genericName":"Vonoprazan Tablets","companyName":"Humanis Saglık Anonim Sirketi","companyId":"humanis-sagl-k-anonim-sirketi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vonoprazan is a small molecule medication used to treat Helicobacter Pylori infection and gastritis, typically in combination with other medications such as amoxicillin and clarithromycin. It is administered as a tablet and has been studied in clinical trials for its efficacy in eradicating Helicobacter Pylori in adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}